Registry for triple-negative breast cancer and inherited mutation carriers
Part of Cancer, Genetic & congenital, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer, or you carry an inherited HBOC gene mutation
- If you have triple-negative breast cancer, you must be within 5 years of your diagnosis
- Triple-negative means ER and PR are very low (less than 10%) and HER is negative on standard testing
- If you carry an HBOC mutation, it must be considered harmful or “uncertain,” not just a harmless DNA variation
- You may be any age, and the trial allows people with or without a personal history of cancer (for mutation carriers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at how different cancer prevention approaches affect women with harmful (deleterious) BRCA1 or BRCA2 mutations. It may help improve future prevention and follow-up plans for women at higher inherited risk.
This study helps people in Switzerland who already have a known inherited cancer gene change understand what it means for them and their family. It focuses on people with specific known mutations related to hereditary breast/ovarian cancer and Lynch syndrome.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This study looks at which DNA “repair” gene changes are found in breast cancer patients, especially certain subtypes and high-risk situations. Your genetic test results may help researchers understand who has specific DNA repair pathway mutations and how they relate to breast cancer.
This study examines how different molecular subtypes (patterns of genes and proteins) of breast cancer behave in people with BRCA1 or BRCA2 mutations. By studying tumor samples and medical records, researchers hope to better predict which treatments will work best and predict long-term outcomes for BRCA-positive breast cancer patients.
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.